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Abstract
Sickle cell disease (SCD) is a haematological disease that affects mul-
tiple organs, thus eliciting episodes of chronic pain, acute anaemia 
and infection, due to a single nucleotide mutation in the β-globin 
gene, which results in the substitution of a glutamic acid residue in 
place of valine on the β-globin chain of the resultant haemoglobin 
protein molecule, the sickle haemoglobin (HbS). SCD is a major cause 
of morbidity and mortality characterized by episodes of vaso-occlusive 
crises, pain syndromes and end organ dysfunctions. Its global pre-
valence is highest in Sub-Saharan Africa with 75% of global births 
living in this region, of which Nigeria has the highest number of SCD 
patients with about 100.000 births each year. The burden of SCD in 
the sub-Saharan region of Africa is enormous. Emotional, financial and 
total healthcare costs are monumental. An understanding of the me-
chanism underlying the vaso-occlusive crises, pain syndromes, inflam-
matory conditions and other sequelae of SCD appears to be essential 
in providing more rational treatments. The present review discuses the 
prevalence of SCD in Africa, molecular mechanisms underlying SCD 
episodic crises including vaso-occlusive syndrome, anaemia and in-
fection. Current available treatments modalities in Sub-Saharan Africa 
and possible new treatment methods that cure SCD are re-examined 
in light of these mechanisms.
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Introduction
Sickle cell disease (SCD) is a haematological disea-
se that affects multiple organs through episodes of 
acute illnesses such as chronic pain, acute anaemia 
and infection, in both children and adults. The di-
sease develops due to a single nucleotide mutation 
in the β-globin gene, which results in the substitu-
tion of a glutamic acid residue at the 6th position 
into a valine on the β-globin chain of the resultant 
haemoglobin protein molecule, the sickle haemog-
lobin (HbS). This causes the formation of a defective 
protein that affects the structure of the red blood 
cell (RBC), producing a sickle shaped cell [1]. As an 
autosomal recessive disorder, SCD is the one of the 
most common monogenic disorders known and it 
is characterized by phenotypic heterogeneity due 
to occurrence of various types of mutation in the 
β-globin gene [2]. The predominant clinical phe-
notype is the homozygote HbSS otherwise called 
the sickle cell anaemia (SCA), while other complex 
heterozygotes also exist due to different mutation 
in the β-globin gene. For instance the HbS-β tha-
lassemia, HbSC (with HbSS in Africa), HbSO and 
HbCO (Arab) and HbD (Punjab) all exist to consti-
tute what is known as SCD [3-5]. The African HbS 
globin haplotypes are present in three geographical 
locations, Senegal, Benin and Bantu regions with a 
fourth Arab-Indian haplotype believed to have origi-
nated from Arab slave trades in Africa [6]. The HbS 
gene exists in high frequency in populations that 
experienced a selective pressure from Plasmodium 
falciparum, a protozoan agent for malaria because 
the resulting HbAS heterozygote is conferred with 
some form of protection against the deleterious 
consequences of malaria. As such, SCD exists in 
high prevalence in areas where malaria is endemic. 
SCD is a major cause of morbidity and mortality, 
and its global prevalence is highest in Africa, South 
America, India, Middle East and the Caribbean [7]. 
The highest global prevalence of SCD is in Sub-Sa-
haran Africa with 75% of global births existing in 
this region and within this region, Nigeria has the 
highest number of SCD patients with about 100,000 
births each year amounting to 33% of global an-
nual births [8, 9]. It has been reported that child-
hood mortality due to the disease in Africa ranges 
between 50-90%, although accurate information 
on this information is still lacking [10]. According to 
the World Health Organisation, 70% of deaths of 
SCD patients in Africa is preventable through low 
cost interventions such as new born screening for 
early identification of SCD patients and compre-
hensive care provision for disease prevention [11]. 
Although, increased incidence of mortality in chil-
dren has been nearly eliminated in North American 
continent due to advancement in medical care and 
new born screening as well as provision of pro-
phylactic antibiotics and pneumococcal vaccinations 
to prevent infection [12, 13], these still constitute a 
disease management that is not curative. The major 
forms of treatment available in this part of the world 
with significant effect include heamatopoietic stem 
cell transplant (HSCT), bone marrow transplant and 
red cell transfusion. Currently, only HSCT successfu-
lly carried out using stem cells or haematopoietic 
stem cells that have been genetically modified (gene 
therapy) can result in total cure by restoring normal 
erythropoiesis [14]. 
With the exception of South Africa where there 
are stem cell transplant centres [15], unfortunately 
in most parts of Africa, there is currently no cura-
tive treatment and the major form of treatments 
that have been in use in the region includes blood 
transfusion and prophylactic treatments. For instan-
ce, a new study reported that health care centres 
in Nigeria now prescribe patients with hydroxyurea 
(for those who can afford the drug when prescri-
bed), folate supplements and penicillin prophylaxis 
[16]. Based on these facts, the treatment modalities 
currently available in sub Saharan Africa does not 
suffice for the burden of morbidity due to the di-
sease in the continent harbouring more than 50% 
of the affected individuals with SCD. Here, we re-
view the current treatment modalities in Africa and 
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suggest ways of better managing the disease as 
well as providing timely and effective treatments 
for patients with SCD.
Results
Signs and Symptoms of SCD
SCD is a haematological disease that stems from the 
production of defective RBCs. Nonetheless, patients 
suffering from the disease presents with a num-
ber of clinical signs and symptoms that represent 
multisystem failure/organ damage. The major symp-
toms are mainly categorized into three; haemato-
logical complications and associated syndromes, 
vaso-occlusive crises and pain syndromes, and end 
organ dysfunction.
Haematological complications and 
associated syndromes
SCD is a disease of the blood and it is mainly asso-
ciated with complications arising from dysfunction 
of the RBCs. Chronic anaemia is a classic symptom 
in SCD patients occurring throughout their lives. De-
pending on genotype, the severity of anaemic crises 
in SCD varies and patients with homozygote HbSS 
experiencing the most severe anaemia due to the 
highest reduction in haemoglobin level, while those 
with β-thalasemia experience the least severe crises. 
Although SCD patients do not present with anae-
mia at birth due to protection from foetal haemog-
lobin (HbF), anaemia arises due to production of the 
adult Hb later in life resulting in acute episodes of 
haemoglobin reduction, hence anaemic crises. Du-
ring the first five years of life, the Hb level remains 
virtually stable, although clinically significant lowe-
ring of Hb do occur at intervals resulting in such 
secondary symptoms as hyperhaemolysis, splenic 
complications, and aplasia. 
Although severe anaemia is a hallmark of SCD, 
hyperheamolysis is characterised with accelerated 
drop in steady state level of Hb with a corresponding 
increased rate of haemolysis. It is also occasionally 
accompanied with increased erythropoiesis, increase 
in steady state reticulocyte count (about 25%) and 
exaggerated hyperbilirubnemia which may result in 
gall bladder disease [8, 17]. Hyperhaemolysis some-
times results during RBC transfusion where delayed 
haemolytic transfusion reaction causes destruction 
of both autologous and homologous RBCs by an 
innocent bystander mechanism. This coupled with 
transfusion induced suppression of erythropoiesis 
leads to the marked increase in haemolysis and is 
often followed with reticulocytopenia [18].
Splenic complications are one of the most obser-
ved crises in patients with SCD particularly those 
with SCA during the early stage of the disease and 
they are associated with increased morbidity and 
mortality. Acute splenic sequestration occurs in the 
first decade after birth and can occur as early as 2 
months after birth due to excessive sequestration of 
both normal and sickled RBC into the spleen often 
resulting in severe anaemia and splenomegaly [19]. 
This thus leads to reduction in the level of RBC/Hb 
present in the blood by > 2g/dL, increased reticulo-
cytosis and thrombocytopenia most times affecting 
packed cell volume [20]. These are the classical signs 
observed during aplastic crisis, although it is usually 
induced by infection such as that of parvovirus B19. 
Infection of erythroid progenitor cells in peripheral 
blood and bone marrow by parvovirus B19 results in 
cessation of erythropoiesis for as much as 10 days 
resulting in severe anaemia due to very short life 
span of RBC in SCD.
Priapism, a painful and prolonged penile erec-
tion occurs in about 30% of adolescents with SCD 
and it is as a result of increased arterial inflow 
of blood with reduced venus outflow causing the 
trapping of RBCs in erectile bodies. It has been 
determined to be associated with increased hae-
molysis, since haemolysis results in depletion of 
nitric oxide (NO), an important smooth muscle cell 
relaxant that plays important role regulating erec-
tile functions [21]. 
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Haemolysis remains a major life threatening event 
in SCD patients mainly because of the secondary 
complications that arises as a result. One of the 
most common symptoms of SCD is the acute chest 
syndrome (ACS) [22]. Adults suffering from SCD are 
at high risk of developing systemic and pulmonary 
hypertension, impaired vasodilatation due to chan-
ges in the intima and smooth muscles of blood ves-
sels, and endothelial dysfunction [23]. With disease 
progression and age, there is increase in the bur-
den of morbidity due to end organ failure such as 
avascular bone necrosis as a result of bone marrow 
infarction, chronic nephropathy due to haematuria, 
hyperfiltration, microalbuminuria and proteinuria, 
and haemorrhagic and non-haemorrhagic stroke 
[24-26]. 
Vaso-occlusive crises and pain syndromes
Vaso-occlusion is the major symptom and complica-
tions observed in SCD patients resulting ultimately 
in painful episodes [27, 28]. Vaso-occlusion arises 
due to the obstruction of micro-vessels consequent 
of trapped sickled RBCs resulting in ischemia in-
duced organ damage and painful episodes lasting 
from few hours to days or even weeks beginning 
from early childhood to adolescence, aggravating 
in adulthood when there may be persistent acu-
te pain in the bones and joints. It results in body 
pains affecting different parts of the body and it is 
believed also to be the cause of priapism and sple-
nomegaly due to acute splenic sequestration [29] 
as stated above. Recurrent acute pain episodes may 
result in neurological changes that may heighten 
sensitivity to pain. ACS is also a common occurren-
ce in SCD characterised with chest pain, wheezing, 
cough, refractory hypoxemia and tachypnea, and it 
is as a results of the obstruction of micro-vessels by 
sickled RBCs [30].
Leg Ulcer
Leg ulcers are relatively common complications of 
SCD and can be debilitating. It is uncommon in the 
first decade of life. Pathogenesis of chronic leg ulcers 
in SCD is complex and may be due to the following 
factors: 1) Mechanical obstruction of the microcircu-
lation by dense sickled RBCs, 2) bacterial infections, 
3) chronic anaemia due to hemolysis with decrease 
in RBCs oxygen carrying capacity, 4) decreased nitric 
oxide bioavailability leading to impaired endothelial 
function. Production of endothelin-1, a potent vaso-
constrictor and subsequent increased expression of 
endothelial cells adhesion molecules, thrombosis 
and venous incompetence have all been proposed 
as potential contributing factors [31, 32]. 
Most of the time it is on the dependent part, 
especially the lower extremities that are involved, in 
areas with thin skin, less subcutaneous fat and with 
decreased blood flow (Figure 1). Trauma and in-
flammatory conditions may be the initiating factors. 
End organ dysfunction
Advancement in treatment of SCD has increased the 
survival rate in SCD patients but due to frequent epi-
sodes of haemolytic anaemia, ischemia and reperfu-
Figure 1:  A photomicrograph showing a leg ulcer 
that resulted from a trauma more than 
one year ago in a 25 years old female 
SCD patient. The ulcer is necrotic, with 
gangrenous borders, full thickness skin 
loss, destruction of other supporting 
structures and possible accompanying 
osteomylitis. SCD = Sickle cell disease
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sion injury in different organs, this group of people 
develop progressive organ dysfunction and eventual 
organ failure. SCD is associated with cardiovascular 
abnormalities due to increased cardiac output and 
resultant morphologic and physiologic changes to 
the cardiac system. Such changes include thickened 
ventricular septum, left ventricular hypertrophy and 
abnormal left ventricular diastolic function leading 
to overt cardiovascular dysfunction [33]. Pulmonary 
hypertension is a common end organ complication 
that is seen in about 30% of SCD adults, posing a 
major life threat and increasing mortality. Patients 
with pulmonary hypertension have reduced NO in 
the circulation due to chronic anaemia and as a 
consequent, there is development of vasculopathies 
characterised with endothelial dysfunction, increa-
se in vascular tone, hypercoagulability and remode-
lling/destruction of the pulmonary vasculature [34]. 
Such patients present with ACS accompanied by 
severe pain that is ameliorated with NO inhalation. 
Patients with ACS present with cough, fever, chest 
pain, hypoxia, dyspnoea and wheezing due to pul-
monary infection that arises from colonisation of 
the upper respiratory tract with bacteria or viruses 
such as E. coli, Streptococcus pneumonia, Staphylo-
coccus aureus and Haemophilus inﬂuenzae [22, 35]. 
Bone marrow infarction and subsequent pulmonary 
infarction or fat embolism due to thromboembo-
lism in micro-vessels have also been observed from 
autopsy reports of SCD patients and has also been 
associated with SCD and as such can be diagnosed 
using bronchioalveolar lavage to examine lipid laden 
macrophages [36]. 
Pathophysiology of SCD
Molecular mechanisms of RBC membrane 
fragility and haemolysis in SCD
The normal Hb molecule is highly soluble and its 
solubility is the main property that allows RBCs to 
easily bind the molecule in high concentration to 
facilitate transport of oxygen molecule efficiently. 
The RBCs possess structural flexibility that aids 
loading and unloading of oxygen molecules, thus, 
when the Hb molecule is deoxygenated and passed 
into the microcirculation, it undergoes a structural 
change to allow oxygenation traversing the pulmo-
nary circulatory system. The replacement of gluta-
mic acid in the β-globin molecule of HbS with vali-
ne results in hydrophobic interaction between ad-
jacent deoxy-HbS molecules on the β-globin chain 
forming polymeric units. This event characterises 
the initiation, chain extension and stabilisation of 
a polymeric fibre of deoxy-HbS moieties which also 
groups together forming a fragile structure that dis-
rupts the cytoskeletal framework and stiffens the 
structure of RBCs resulting in a sickled shape cells 
with very limited structural flexibility or reduced de-
formability [6]. The polymeric deoxy-HbS fibre in 
turn triggers the activation of signalling cascades 
that initiates the pathophysiological mechanism. 
Because of the rigidity of the cell, dysregulation 
of ion transport across the membrane is affected. 
Most importantly, there is activation of ion channels 
such as the calcium dependent potassium channel 
(Gardos channel) and the potassium chloride co-
transport system activation of which causes an inf-
lux of Ca2+ and a concomitant outflux of K+ resul-
ting in RBC dehydration. This in turn increases the 
intracellular concentration of Hb and thus favours 
polymerisation of more deoxy-HbS [37]. Intracellu-
lar hemichromes from denatured Hb interacts with 
band 3 proteins, spectrin and actin leading to loss 
of Fe3+ from the heme creating an oxidising en-
vironment that disrupts the polarity of membrane 
phospholipids, particularly flipping of phosphatidyl-
serine to the outer membrane surface. The mutated 
β-globin molecule also undergo auto-oxidation to 
form the superoxide (O2-) produced during reoxyge-
nation of Hb to form methaemoglobin, which in 
the presence of hydrogen peroxide (H2O2) decom-
poses the Hb releasing free iron to create a highly 
oxidising microenvironment [38]. Ca2+-calmodulin 
complex activates the erythrocyte adenosine mo-
nophosphate deaminase (AMPD) and increases the 
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intracellular level of inosine monophosphate (IMP) 
from deamination of AMP, rendering the cell energy 
deficient and in turn increasing the translocation of 
phosphatidyl-serine to the outer membrane surfa-
ce [39]. These processes results in RBC membrane 
fragility and eventual haemolysis.
Pathophysiology of vaso-oclussion
RBCs fragility and stiffness are both respectively 
responsible for the haemolysis and obstruction of 
microcirculation that results in vaso-oclussion, both 
of which characterise the pathophysiological bases 
of SCD. Vaso-oclussion arises due to adhesion of 
sickled RBCs to the endothelium of micro-vessels 
resulting in the obstruction of blood flow and sub-
sequently ischemia in affected tissues. Vaso-oclu-
sion is propagated in two phases. In the first, the 
reticulocytes produced prematurely in the bone ma-
rrow in an attempt to relieve anaemic stress adhere 
to blood vessels with the aid of various adhesion 
proteins expressed on their cell surfaces. This re-
duces the velocity of RBC in the microcirculation, 
maintaining the RBC in a hypoxic environment long 
enough for the formation of deoxy-HbS and Hb po-
lymerization into fibres. In the second phase, sickled 
RBCs are entrapped in the micro vessels by binding 
to endothelial cells via different adhesion proteins 
[40]. Sickle RBC binding to the endothelium is fa-
cilitated by processes and factors such as the Von 
Willebrand factor (vWF) bridging intergrin receptors 
with similar receptors on endothelial cells of large 
vessels, binding of α4β1 on sickled RBC to vascular 
cell adhesion molecule 1 (VCAM-1) on endothelial 
cells in micro-vessels, bridging of CD36 on sickled 
RBC with αvβ3 integrin receptor on endothelial cells 
by plasma thrombospondin and binding of sickled 
RBCs to E- and P-selectins on cytokine activated 
endothelium [41]. 
It is known that the endothelium plays a crucial 
role in development of vaso-oclussion by mediating 
RBC adhesion through the expression of several 
adhesion molecules/receptors such as VCAM-1, 
Lu/BCAM, c-type lectins (selectins), and CD36 on 
the surfaces of endothelial cells, and the molecu-
lar mechanisms that triggers endothelial activation 
till date are not fully understood [42]. In SCD, the 
activation of endothelial cells result in endothelial 
dysfunction and aberrant adhesion molecule ex-
pression often characterising a deviation from basal 
quiescent state of endothelium to a more active 
state [42]. This activation is believed to be triggered 
in part by processes due to sickled RBCs haemoly-
sis such as heme liberation and release of inflam-
matory cytokines from cytolysed sickled RBCs. In 
a murine sickle cell model, heme activated nuclear 
factor kappa-β (NFкβ) of endothelial cells causes 
degranulation of Weibel-Palade body (WPB) by mo-
bilising WPB, vWF and P-selectin to the surface of 
the cells and endothelial walls through the action 
of toll-like receptor 4 (TLR4) [43]. Oxygen radicals 
produced from the interactions of sickled RBCs 
with the endothelium and subsequent activation of 
endothelial NFкβ also up-regulate the transcription 
of adhesion molecules such as VCAM1, E-selectin 
and ICAM1 giving the circulating endothelial cells 
an activated phenotype through the expression of 
these adhesion molecules (Figure 2) [44, 45]. P- 
and E-selectin have been suggested to be potential 
factors in the development of vaso-oclussion but 
the implication of P-selectin in the pathogenesis of 
vaso-oclussion and as a potential therapeutic tar-
get is further emphasised by reduced sickled RBC 
and leukocyte adhesion to endothelium and increa-
sed microvascular blood flow in SCD mice treated 
with anti-P-selectin antibody [46]. We are also of 
the opinion that inflammatory cytokines produced 
during infection and during RBC haemolysis play 
significant roles in the expression endothelial cell 
adhesion molecules/receptors. 
An in vitro study also demonstrated the role of 
platelets in endothelial activation in SCD patients 
since platelets circulate in an activated form in the-
se patients. Steady state SCA platelets co-cultured 
with human umbilical endothelial cells (HUVEC) ac-
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Figure 2:  Schematic illustration of proposed mechanisms underlying increased adhesion of sickled RBCs 
to vascular endothelium and vaso-constriction leading to episodic pain syndromes, leg ulcers 
and organ dysfunctions in SCD: Rupture of RBCs could result in systemic infection anae-
mia and release of cellular molecules such as heme, arginase, superoxides and inflammatory 
cytokines. This could lead to activation of NFkβ and reduced NO production through release 
of the cellular molecules or increased production of immature reticulocytes consequent of 
anaemia. These factors thus could result in increased expression of adhesion molecules that 
will mediate binding of sickled RBCs to endothelial surface of the vasculature causing vaso-
occlusive episodes.
Heme and Arginase
Cytokines
Oxygen free radicals 
Increased expression of endothelial 
adhesion molecules/receptors 
(VCAM-1, ICAM-1, Intergrins, E&P 
Selectins, CD36 , vWF, WPB, etc)
Decreased RBC 
microvasculature velocity
Increased adhesion of sickled RBC & vaso-constriction
Episodic pain syndromes, ulcers and organ dysfunctions
RBC fragility and hemolysis in SCD
Anemia
Systemic infection
Activation of NFkβ
IL1β
Met Hb, Nitrates, Arginase 
brake down argentine sub 
for eNOS
Reacts with NO on 
endothelial cells
Endotheliine – 1
Increased production of 
Immature recticulocytes
Loss of NO 
eNOS = endothelial nitric oxide synthase , IL1β = Interleukin -1 beta, RBC = Red blood cell , SCD = Sickle cell disease, NFkβ – nuclear factor kappa beta, 
VCAM-1 = vascular cellular adhesion molecule 1, ICAM-1 = intracellular adhesion molecule -1, E&P Selectins, vWF = Von Willebrand factor, WPB = Weibel-Palade body, 
NO = nitric oxide, E-Selectins = endothelial-leukocyte adhesion molecule 1.
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tivated the endothelial cells (EC) through activation 
of EC NFкβ and increased IL1β expression and a re-
sulting high expression of adhesion molecules such 
as ICAM1 and E-selectin [47]. 
Aside endothelial activation, endothelial dys-
function which is characterised by the reduction in 
NO produced by endothelial cells is another con-
tributor to development of vaso-oclusion. NO is a 
major vasodilator produced by nitric oxide synthase 
(NOS) through conversion of arginine to citrulline. 
NO, after production traverses the endothelial cell 
membranes to bind guanylate cyclase converting 
GTP to cGMP in smooth muscle cells, subsequently 
activating cGMP-dependent protein kinases that 
mediates vasodilation. During haemolysis, there is 
release of heme and arginase into the circulatory 
system. Heme reacts with NO forming nitrates and 
metHb while arginase breaks down arginine which 
is a substrate for NOS to replenish the scavenged 
NO (Figure 2) [48, 49]. This in turns leads to increa-
sed expression of endothelin-1, a vasoconstrictor, 
resulting in vasoconstriction and vaso-oclusion. In-
terestingly, it has been previously demonstrated that 
NOS gene therapy down-regulates the expression of 
ICAM1, VCAM1, E- and P-selectin, and inhibits the 
activation of platelets [50, 51]. This then suggests a 
role for NO in endothelial inactivation and further 
strengthens the fact that reduced bioavailability of 
NO in SCD may contribute to platelet activation and 
increased expression of adhesion molecules.
Current and emerging therapeutic 
strategies in the treatment of SCD
Fundamentally, apart from the prophylactic 
treatment such as Pneumococcal vaccination and 
penicillin injection given to SCD infant during early 
diagnosis, the treatment of SCD is based on either 
disease management procedure or a curative stem 
cell therapy (all discussed below), both of which ex-
hibit a level of complications that are currently being 
investigated.
Prophylactic therapy
There are currently three prophylactic treatments 
that are widely accepted and predominantly in 
use; penicillin prophylaxis, pneumococcal vaccina-
tion and folate supplement. Penicillin prophylaxis is 
provided to infants shortly after birth and diagno-
sis of SCD. This is because within the first 5 years 
of life, SCD patients are prone to life threatening 
pneumonia infection due to vaso-oclusion in the 
spleen preventing antibody production against en-
capsulated micro-organisms such as Streptococcal 
pneumonia and Haemophilus inﬂuenza, and inabili-
ty of the spleen to also produce complement factors 
and C-reactive proteins for bacteria sensing, recog-
nition and phagocytosis. This thus result in chronic 
infection that can lead to death in the first 24 hrs 
from onset of the infection [52-54]. Immediately af-
ter diagnosis or at least by 2 months of age, SCD 
patients under the age of 5 years are treated with 
125 mg of penicillin VK twice daily. This dosage is 
increased to 250 mg twice daily for patients over 
the age of 5 [54]. Because of the decline in episo-
des of infection in older SCD patients and ability to 
develop immune response, penicillin prophylaxis is 
advised to be discontinued to prevent development 
of resistant strains.
Pneumococcal infection is a common occurren-
ce in SCD patients and the use of pneumococcal 
vaccines widely is to prevent this in SCD patients 
under 5 years of age. The vaccination involves im-
munisation with a heptavalent protein conjugate 
vaccine (PCV7) at ages 2, 4, 6 and 12 months. This 
is followed with immunisation with a tricosavalent 
pneumococcal polysaccharide vaccine at 2 and 5 
years [55]. Because of the increased rate of folate 
turn over due to megaloblastic anaemia and bone 
marrow aplasia associated with haemolytic anae-
mia, SCD patients are treated with 1 mg of folate 
daily [56]. 
In addition to the above therapeutic combina-
tion, because of the prevalence of malaria amongst 
SCD patient in Nigeria and other parts of Sub Sa-
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hara Africa, treatment with anti-malaria prophylaxis 
is often recommended to reduce episodes of crisis 
[57]. The most commonly used treatment ranges 
from combination of arthemisin based drugs to the 
use of insecticide treated nets. Chemoprophylaxis 
with proguanil or pyrimethamine is also widely used 
and has been found to reduce sickle cell crises [57, 
58]. Daily dosage of 100 or 200 mg of proguanil or 
weekly dosage of 125 or 250mg mefloquine have 
also been shown to reduce sickle cell crises with at 
least 80% success rate and both regimen having 
comparable outcomes [59].
SCD treatments aimed at disease 
management
Hydroxyurea for HbF induction
In the first few months to couple of years of life, 
new born with SCD are prevented from vaso-oclu-
sive and anaemic crises that characterise SCD due 
to the expression of HbF. HbF interferes with HbS 
polymerisation preventing the formation of deo-
xy-HbF polymeric fibre at a concentration that is 
enough to have toxic effect on the RBC. It has been 
reported that in compound heterozygotes of SCD 
trait having hereditary persistence of HbF expres-
sion is advantage. Twenty percent HbF is enough 
to prevent SCD crises even when there is about 
80% HbS in the RBC [60]. Erythroid progenitors 
have high HbF levels and due to stringent differen-
tiation and slow clonal expansion, only about 3% 
of circulating RBCs of adults contain a detectable 
concentration of HbF. Thus with rapid expansion 
of progenitor cells, the retention of γ-globin gene 
expression of HbF in RBC is maintained. There-
fore, drugs such as 5-azacytidine and its analo-
gues have been developed to induce expression 
of HbF through destruction of late erythroid pro-
genitors that favour expression of β-globin gene 
of adult Hb. This results in accelerated expansion 
of erythroid progenitors into RBCs containing high 
HbF levels. Due to gross gene hypomethylation 
and cytotoxicity of these class of drug, their use 
in the treatment of SCD is currently not appro-
ved. Hydroxyurea is the only drug approved for 
HbF induction to prevent vaso-oclussive crises and 
perhaps the most successful drug in the treatment 
of SCD [58]. Hydroxurea acts by inhibiting ribonu-
cleotide reductase, an enzyme that converts ribo-
nucleotides to deoxyribonucleotides, thus, halting 
DNA synthesis [58].
Treatment with hydroxyurea is applicable to SCD 
patients of all ages [61] and it is recommended sub-
sequent to presentation of symptoms such as pria-
pism, persistent anaemia, vaso-oclussion related 
crises (more than 3 hospital admissions per year) 
and ACS. Starting dose of hydroxyurea is 15 mg/
Kg/day which is increased by 5 mg/Kg/day every 3 
months up to a maximum of 35 mg/Kg/day. Be-
cause of the effect of the drug on hematopoiesis, 
patients are closely monitored at 2 week intervals 
for complete blood counts to detect bone marrow 
aplasia. In adults that cannot tolerate the starting 
dosage, 500 mg/day dosage can be applied and 
the blood count checked fortnightly in many Sub 
Saharan centres. In the event of myelotoxicity, the 
drug is withheld for 2 weeks until stable blood 
count is achieved. When recurrent or persistent 
myelotoxicity occur, dosage may be reduced gra-
dually by 2.5 mg/Kg/day until stable conditions are 
observed. Afterwards complete blood count may 
be monitored monthly for changes in platelet and 
leukocyte counts. 
Hydroxyurea is a well-tolerated drug and treatment 
with hydroxyurea is associated with significant re-
duction in hospital admissions due to vaso-occlusive 
crises, ACS, priapism and hepatic complications [56]. 
Its effectiveness in preventing stroke is controversial 
anyway [62], but a clinical trial investigating this is 
currently underway [63]. On the contrary, there is 
increasing evidence that long term use of hydroxyu-
rea has suggested by some studies, results in leu-
kaemia in patients with essential thrombocytemia 
and polycythemia vera [64, 65], although a study in-
volving 299 adult SCD patients found no association 
InternatIonal archIves of MedIcIne
Section: internal Medicine & HoSpital Medicine 
Issn: 1755-7682 J
2015
Vol. 8 No. 185
doi: 10.3823/1784
This article is available at: www.intarchmed.com and www.medbrary.com 10
between 9 years treatment with hydroxyurea and 
development of leukaemia of any sort [66]. Thus, 
there is need for a well-structured long term stu-
dy that will further investigate association between 
treatment with hydroxyurea and leukomogenic risk 
in SCD patients.
Replenishment of circulating NO for vaso-occlusion 
treatment
NO is a known major vasodialator produced by 
endothelial cells and it plays a key role in vaso-
occlusive crises of SCD [67, 68]. Although there is 
increased expression of NOS in SCD, the disease is 
characterised with inactivation of NOS, resistance 
to NO and impaired NO bioavailability resulting in 
vaso-occlusive related crises such as pulmonary hy-
pertension and ACS [34, 69, 70]. As such, different 
studies have been designed to target increasing the 
bioavailability of circulating NO to compensate for 
the deficiency thus observed. A study showed that 
inhalation of NO significantly reduced the depen-
dence of patient on morphine for pain relief after 6 
hours of NO inhalation (0.26 mg/kg vs 0.44 mg/kg, 
case vs placebo group respectively, p = 0.03) and a 
1 cm/h reduction in pain score compared to place-
bo group (p = 0.02) [71]. Because of the important 
role played by arginine in the biosynthesis of NO 
and pathogenesis of vaso-occlusion in SCD, several 
studies now look at the use of arginine supplements 
in treating vaso-occlusion. However, no standard 
dosage exists as yet. Patients treated with oral 100 
mg/kg of L-arginine HCl thrice daily for 5 days had 
15.2% reduction in arterial systolic pressure (63.9 
± 13 mmHg to 54.2 ± 12 mmHg, p = 0.002) (72). 
A recent randomised control trial reported that 100 
mg/Kg L-arginine supplementation reduces opioid 
use for pain relief by 54% (1.9 ± 2.0 mg/kg vs 4.1 
± 4.1 mg/kg, admission vs discharge respectively, p 
= 0.02) and 50% reduction in pain score (1.9 ± 2.4 
vs. 3.9 ± 2.9, admission vs discharge respectively, p 
= 0.01) [73]. 
RBC transfusion 
RBC transfusion in treating SCD is a major disease 
management procedure in adult patients with di-
sease complications and vaso-occlusive crises and 
about 90% of adults suffering from SCD will recei-
ve this treatment at some point in their lives [74]. 
However, there is need to thoroughly consider the 
risks and benefits of the procedure to maintain a 
risk-benefit balance and avoid further disease com-
plications and waste of resources. The major risks 
associated with transfusion include iron overload, 
increased blood viscosity, alloimmunisation against 
donor blood cells and delayed haemolytic transfu-
sion reactions. Nonetheless, the requirement and 
recommendations for the use of RBC in treating 
SCD is increasing due to increased sophistication in 
the procedure with the availability of iron chelators 
and erythrocytapheresis to treat iron overload as 
well as extended phenotype matching for alleviating 
alloimmunisation.
Indications for the recommendation of RBC 
transfusion include transient RBC aplasia, ACS, 
splenic sequestration induced hypovolemia, acute 
multi-organ failure and stroke, acute exacerbation 
of anaemia and pre-surgery blood transfusion for 
SCD patients [74-76]. Irrespective of the cause or 
requirement for transfusion, the need for the proce-
dure should be based on the inability of the patient 
to compensate for the loss of Hb due to anaemia. 
As asymptomatic patients with moderate or even 
severe anaemia have a steady state reduction in 
Hb level, undergoing transfusion can lead to unwa-
rranted and avoidable complications. Simple RBC 
transfusion are frequently used in event of acute 
splenic sequestration and transient RBC aplasia but 
patients with the latter are transfused with adequa-
te monitoring of the Hb level which will increase 
as the disease alleviates. Transfusion with aliquots 
of 5 ml/Kg spaced over some hours up till Hb level 
rises to 10 mg/dl so as to avoid hyperhemoglobi-
nemia post-transfusion due to disease alleviation 
[77]. In patients with acute ischemic stroke, chronic 
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transfusion can be used to prevent future episodes 
of the disease and can also prevent the disease 
development in high risk patients diagnosed early 
with transcranial Doppler ultrasonography [78] but 
recent studies have shown that patients that under-
go chronic transfusion for prevention of recurrent 
stroke often develop cerebral vasculopathy and ce-
rebral infarction [79-82].
Emerging treatment strategies
Use of African traditional medicines
There are some African traditional medicines that 
have shown great potentials in the stimulation of 
hematopoietic cells to rapidly produce blood and 
correct anaemia. It has also been suggested that 
they may be acting by increasing the population of 
circulating HbF. They may also be acting on any of 
the molecular pathways described above. Howe-
ver, these traditional medicines need purification 
to isolate active ingredient(s) and subjected to cli-
nical trials before they can be widely used in SCD 
treatment.
Hematopoietic stem cell transplantation (HSCT) and 
gene therapy
HSCT is the only curative measure available for SCD 
treatment and considering the prevalence of the di-
sease, it is still an underutilised form of treatment. 
Recommendation of HSCT is often limited becau-
se of rare existence of HLA-matched sibling donor 
(MSD). Apart from this, there are some associated 
complications such as graft versus host disease 
(GVHD) and post-HSCT toxicity. Children below 16 
years stand a high chance of having successful HSCT 
due to absence of age-related comorbidities and 
organ failure. Advancement in research could help 
push the application of the procedure to older age 
groups with the use of reduced intensity treatment 
(RIT), a multistep strategy where immunosuppressi-
ve agents are used in low doses to prevent organ 
toxicities [83]. RIT procedures vary for each patient 
and the procedure is not to be considered the same 
across population. In adult patients with advanced 
disease comorbidities, HSCT often results in high 
morbidity and mortality rate. However, presentation 
with recurrent stroke, hypertension and renal dys-
function, or patients at high risk of pulmonary com-
plications and sudden death, qualifies for conside-
ration for the procedure as benefits of performing 
HSCT can outweigh the complications. In this case, 
a matched unrelated donor (MUD) can be conside-
red with the implementation of RIT if there is no 
MSD, showing the potential of using this treatment 
modality to increase donor pool irrespective of HLA 
status. A RIT trial in 14 patients treated with fluda-
rabine, alemtuzumab and melphalan using MSD or 
MUD marrow produced a 95% overall and 79% 
event free survival rate in these patients [14]. RIT 
HSCT trials are currently underway at the National 
Institutes of Health and Blood and Marrow Trans-
plant-Related Clinical Trials Network (BMT CTN) 
Sickle Cell Unrelated Transplant (SCURT) and it is 
currently in practice at the John Hopkins School of 
Medicine [84]. 
Apart from RIT-HSCT, a recent study showed that 
genetically modifying β-globin (autologous hema-
topoietic stem cell gene therapy) and subsequently 
transferring this gene into bone marrow stem cell 
to be transplanted could help reduce post-HSCT 
complications and other associated morbidities 
[85]. A lentiviral vector encoding wild type human 
Hb gene modified to impair HbS polymerisation 
was transferred into bone marrow CD34 to trans-
duce the patients’ HbS and thus prevent formation 
of sickled RBC. This study showed efficient trans-
fection of the lentiviral vector and effective trans-
duction of SCD bone marrows’ CD34 progenitor to 
produce normal Hb and this could be moving into 
clinical trial soon. 
Conclusions
In summary, the burden of SCD in sub-Saharan 
region of Africa is enormous. Emotional, financial 
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and total healthcare costs are monumental. Unfor-
tunately, despite the burden of SCD in sub-Saha-
ran Africa, there are no centres offering these new 
treatments methods or currently using molecular 
approaches in the treatment of SCD. Although 
more awareness about SCD and its complications 
is increasing in the region, research focusing on mo-
dern treatment methods is almost non existence. 
Targeting adhesion molecules known to circulate 
in the blood of SCD patients and or expressed on 
endothelial cells may lead to the development of 
treatments that will see a reduction in adhesion of 
sickled RBCs to the endothelium hence preventing 
vaso-oclusive episodes. Periodic monitoring of their 
plasma levels using molecular methods and subse-
quent administration of neutralizing antibodies may 
be a potent preventive measure. New research fo-
cusing on the molecular mechanism of vaso-oclusi-
ve syndromes may lead to further identification of 
molecular targets that can improve SCD treatments 
in the sub-Saharan region of Africa. SCD being a 
single gene defect will be adequately treated using 
the newly developed stem cell gene therapy and 
HSCT in sub-Saharan region of Africa.
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